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Abstract
The first session at the 2016 Syphilis Summit provided an opportunity for laboratory researchers 
and clinicians to comment on gaps in biomedical knowledge and technologies. Predominant 
themes in the presentations and discussion included the need for optimization of existing 
diagnostic tests, commercial availability and FDA approval of nucleic acid amplification tests for 
primary and secondary syphilis, development of sensitive and specific new blood tests for 
diagnosis of active (vs. treated) syphilis infection, clarification of the best measures for adequacy 
of response to treatment, continued study of complications of syphilis including neuro- and ocular 
syphilis, and development of a safe and effective vaccine that will protect against transmission and 
complications of disseminated infection (including congenital and neurosyphilis). Renewed and 
sustained support of biomedical syphilis research and an influx of talent could move the needle in 
the fight against this re-emerging ancient disease.
Keywords
Syphilis; vaccine; neurosyphilis; diagnosis; treatment; prevention
INTRODUCTION AND OVERALL FINDINGS
In recent decades, syphilis elimination appeared within reach. Unfortunately, not only has 
syphilis re-emerged, but the biomedical research landscape is also left with limited human 
and financial resources to counter rising rates. The purpose of the first session was two-fold: 
first, to provide a rare opportunity to bring together remaining biomedical syphilis experts, 
and second, to seek their counsel for setting research priorities. These are listed below. In 
addition, several noteworthy themes were discussed:
• There are many open basic research questions on the natural history of syphilis. 
Much of our “knowledge” concerning the natural history of syphilis arises from 
studies conducted in the pre-antibiotic era, and these may be confounded by 
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other medical conditions not recognized at the time. This includes a more in-
depth definition of specific immune responses, the antigens that trigger such 
responses, and the level of protection induced by these responses, as defined with 
modern immunological approaches in both the rabbit model and in human 
infection. This will require development of immunological reagents for the 
rabbit, which is an excellent small animal model for syphilis. Research on the 
interaction of syphilis with co-occurring infections such as HIV should be 
included. Many questions remain unanswered despite the public’s long 
awareness of the disease and despite substantial biomedical advances for more 
recently emergent infections such as HIV. The perception among many 
politicians and the public that syphilis has disappeared, and the stigma 
surrounding this infection, has left it the “poor stepchild” in terms of attention.
• Although research has identified potentially improved antigens for diagnostic 
tests, the perceived lack of a market makes many diagnostic companies reluctant 
to invest in development of novel, specific, and sensitive diagnostic tests and 
effective disease management protocols. In addition, protective vaccine 
development has been left wanting and the antimicrobial pipeline has been 
anemic with little advancement since penicillin became available in the 1940s. 
There is a surprisingly thin landscape of development initiatives employing 
modern-day technologies in these areas. Most striking is the lack of an FDA-
approved nucleic acid amplification test for GUD (genital ulcer disease) to better 
diagnose primary syphilis.
• Few experienced biomedical researchers and clinicians remain. It is difficult to 
attract new talent to this field due to the difficulty in working with Treponema 
pallidum and lack of research funding to sustain their careers. For example, 
despite the dramatic rise in syphilis cases, the number of US basic science 
laboratories studying the organism or disease has remained static and low; their 
grant funds have been reduced compared to 10 years ago; and several 
experienced T. pallidum investigators are nearing retirement age. Given the rise 
in syphilis cases, young clinicians in large cities where there are STD Clinics are 
being given the opportunity to see cases of syphilis, but medical schools are still 
not including STDs, other than HIV, in their curricula in proportion to the STD 
problem in the US.
As a follow-up to the summit, the findings were described and disseminated to a diverse 
audience and diverse public health entities in the document “Syphilis Call to Action – Let’s 
Work Together to Stem the Tide of Rising Syphilis in the United States” (1). In brief, CDC 
calls on partners, including biomedical scientists, to develop new tools for syphilis 
prevention, detection, and treatment, and to generate interest in the field. Moreover, 
identified priorities include the following:
1. Develop and bring to market novel syphilis tests to rapidly diagnose active (vs. 
treated) infection in easy-to-obtain samples (including in blood) and in all 
disease stages.
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2. Conduct clinical research to support evidence-based recommendations for 
clinical management of all disease stages, including management of treatment 
non-serologic response, repeated infection, neuro- and ocular syphilis, and 
infection is persons living with HIV.
3. Promote research on effective vaccine design, acceptability, cost, and potential 
impact on the epidemic.
4. Invigorate training of biomedical and clinical researchers, and address basic 
biological research questions (e.g., genetics, immune response, pathogenesis) in 
order to galvanize future technological advances.
What follows is a summary of specific research priorities as identified during the structured 
discussion portion of Unit 1. Experts were invited to respond to five prepared questions, and 
to identify specific research gaps within these topic areas.
RESEARCH PRIORITIES
Structured topic 1
I.1. “How do we optimize the reverse sequence algorithm to minimize 
diagnostic errors or overtreatment? Is there a need for more data collection/
direct comparisons of traditional and reverse algorithms using clinically 
defined specimens?”
Discussion summary: The reverse testing algorithm with its prioritized treponemal test is 
gaining in popularity in US laboratories because it allows automation of the initial test. 
Because of the recognized rate of false positivity in treponemal tests, this change is 
increasingly leading to inaccurate case identification, especially during screening of persons 
in low syphilis prevalence settings. Ensuing problems can be confusion among medical 
providers who receive test results, anxiety and stress for the patient and their partners, and 
harms of potential overtreatment. In addition, there is a lack of clarity on optimal treponemal 
and nontreponemal test selection and interpretation, and on whether and when a second 
treponemal test is needed.
Identified priorities:
• To conduct careful examination of the reactive “cutoff” value, optimal serum 
dilution for testing, modification of the technical aspects of the existing tests to 
minimize false negative reactions while maintaining acceptable sensitivity.
• To explore development of new EIA/CIA tests using other T. pallidum antigens 
(beyond the 3 or 4 antigens used in all current tests).
• To evaluate the use of the reverse sequence algorithm in different scenarios and 
prevalence settings in comparison to the traditional algorithm, including during 
treatment and follow-up. Cost, the role of the epidemiologic context, and health 
care setting should be considerations in the design of evaluations.
• To conduct comparative evaluations of existing treponemal tests using well 
defined clinical specimens from patients with all stages of syphilis and 
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populations for whom screening is recommended. In particular, there is a need to 
address the value, type, and interpretation of a second treponemal test in the 
reverse algorithm.
• To develop evidence-based recommendations for syphilis diagnostic testing, 
including Rapid Testing.
Structured topic 2
I.2. What is the value of Rapid Syphilis Tests (RST) for diagnosis of syphilis in 
the US? Can they be used effectively to stem increases in the US and in what 
settings? Should we be developing another algorithm for RST use?
Discussion summary: There is currently only one FDA-approved, CLIA-waived RST in use 
in the US. It is a treponemal antibody test and does not include non-treponemal antibody 
testing. Its usefulness has not been sufficiently evaluated with regard to patient management, 
performance, and benefit in various settings. Evaluation data and CDC recommendations are 
needed to guide its use, including concerning the suitability of different biological 
specimens, and quality-controlled implementation. Additional POC tests, some already well-
studied in international settings, should be evaluated in the US so that tests with optimal 
sensitivity and specificity can become available for use in the US, particularly in emergency 
rooms and delivery rooms where women lacking prenatal care present for delivery. This 
should include the dual path POC test that includes nontreponemal and treponemal antigens 
and POC tests that also include HIV.
Identified priorities:
• To evaluate test performance in various settings (clinical, including STD clinics, 
outbreak settings, field investigations, community-based organizations (CBOs), 
emergency departments), and compare results to laboratory-based algorithms.
• To evaluate overall outcomes of patient management, morbidity averted, and cost 
when RSTs are used in comparison to the use of lab-based tests.
• To foster research and development of additional treponemal antibody RSTs, 
non-treponemal antibody RSTs, and most importantly, new technologies that will 
ultimately allow rapid identification of active infection by directly detecting T. 
pallidum, especially in whole blood and CSF.
Structured topic 3
I.3. Direct detection of T. pallidum is a challenge in the US today. Few labs 
have the capability to perform darkfield microscopy. PCR detection in primary 
and secondary syphilis from lesion material is possible, but remains a lab-
developed test. How can this assay be standardized and moved forward for 
FDA approval?
Discussion summary: Being able to directly detect active T. pallidum infection especially in 
genital lesions with techniques common to modern laboratories would be a game changer 
for syphilis diagnostics. It would likely allow more accurate and faster diagnosis of infection 
in the most infectious stage (i.e. primary) of syphilis. This has the potential to change patient 
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management by reducing misdiagnoses of primary syphilis. It could also reduce the 
epidemic by allowing more timely treatment of infectious syphilis, thereby preventing 
transmission to sexual partners. Sensitive T. pallidum PCR tests have been developed, but 
have not been cleared by FDA. Their application for differential diagnosis of GUD 
(HSV-1/2, T. pallidum, and other ulcer-causing diseases) is documented but has not been 
substantially implemented. This approach thus has untapped potential for stemming the tide 
of rising syphilis. Recent approvals of several HSV-1/2 PCR assays for genital lesion 
specimens may provide a new opportunity and business model for T. pallidum diagnostics, 
as HSV/T. pallidum multiplexed tests could be used for GUD diagnostics.
Identified priorities:
• To further develop and bring to market HSV/T. pallidum multiplexed PCR tests 
for GUD diagnosis. Additionally, T. pallidum PCR tests in general need to be 
further developed and evaluated in terms of their sensitivity and specificity on a 
range of specimen types, including from a variety of anatomical sites (lesions 
swabs, skin scrapings, blood, CSF, ocular fluid, mouth, urine, amniotic fluid, 
cord blood, placenta).
• POC nucleic acid amplification tests, or other direct detection tests, would be 
particularly useful in STD Clinic settings.
• To explore other technologies or approaches (e.g., MALDI-TOF biomarker 
identification) for diagnosis of active infection
• To create mechanisms for sharing of well-characterized clinical specimens (e.g., 
blood, serum, CSF, amniotic fluid) with associated clinical data for patients with 
all stages of syphilis, those living with HIV, those pregnant, and those with and 
without neurologic complications, as is needed for test development and 
validation.
• Explore development of low tech PCR tests such as LAMP (loop-mediated 
isothermal amplification) for use in low resource settings.
Structured topic 4
I.4. During clinical management of patients after antibiotic treatment, with 
potential reinfection, or during pregnancy: how well do non-treponemal titers 
reflect syphilis disease activity? What clinical decision should be based on 
changes in non-treponemal antibody titers (fluctuation, serofast, fourfold 
decrease)?
Discussion summary: The rate and extent of reductions in antibody titer in response to 
treatment in patients with and without a history of treated syphilis or increases in titer after 
treatment or re-infection remain insufficiently characterized and understood, yet key syphilis 
treatment decisions are based on them. Agreed-upon, standard definitions for rates of 
antibody titer declines that ideally correlate with clinical cure are needed. Moreover, the 
term “serofast” lacks a clear definition, and there is little consensus about when concern is 
warranted regarding serofast or fluctuating titers after treatment, especially in those living 
with HIV or in pregnancy. Therefore, more research is needed, and selected previously 
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conducted studies need to be repeated, using modern techniques and reagents. This should 
include follow-up of adult syphilis in those living with HIV, maternal syphilis, fetal syphilis, 
and congenital syphilis. Many studies have been uncontrolled or retrospective, and are 
therefore difficult to interpret.
Identified priorities:
• To conduct well-designed prospective cohort research on clinical outcomes of 
patients and their serological responses (both non-treponemal and treponemal), 
in persons with or without HIV co-infection, in females with and without 
pregnancy and in neonates with congenital syphilis.
• To explore new biomarkers (e.g., cytokines, T cells responses, others) and other 
technologies (e.g., PET scans, ultrasound [congenital syphilis]) in evaluating 
response to therapy and as measures of active infection.
• A careful study of IgM titers should be conducted, both in untreated persons and 
longitudinally following treatment, to determine whether there is a role for IgM 
in assessing active infection, and in determining efficacy of treatment.
Structured topic 5
I.5. How does HIV modify the natural history of syphilis infection and should 
this impact clinical management? If so, how?
Discussion summary: The interplay of T. pallidum, HIV infection, and host immune 
function remain insufficiently understood, as is the impact of repeated syphilis infections/
treatment and HIV antiretroviral therapy. There is a paucity of data on effectiveness of 
syphilis treatment in HIV-positive persons in the ART and viral suppression era. There is a 
lack of clarity around the potential benefits of more frequent STI screening (i.e., between 
recommended HIV care visits) in people living with HIV. Moreover, awareness of the 
adverse health outcomes of adult syphilis such as neuro-, ocular and otic syphilis has been 
raised in recent years, in both HIV-positive and -negative persons. Addressing the benefits of 
lumbar puncture to guide therapy with a goal of preventing adverse clinical outcomes, and a 
sensitive and specific diagnostic test for neurosyphilis are urgently needed.
Identified priorities:
• To conduct a randomized, prospective cohort study to determine the benefit of 
lumbar puncture at various stages of syphilis to improve clinical outcomes.
• To determine the expected rate of neurosyphilis, ocular, and otic syphilis in all 
stages of syphilis in the post-antibiotic era and post-ART/immune suppression 
era.
• To evaluate timing of syphilis treatment in persons newly diagnosed with both 
HIV and syphilis, particularly with regard to initiation of HIV treatment.
• To develop mathematical models of cost and benefit for frequency of STI 
screening in persons living with HIV.
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• To conduct a longitudinal cohort study of the effect of current anti-retroviral 
treatment on syphilis manifestations, progression, and response to syphilis 
treatment, adjusting for CD4 count and level of immune reconstitution.
CONCLUSIONS AND SUMMARY
The discussion of structured topics allowed experts to discuss concrete, achievable research 
priorities on current issues in syphilis laboratory science and clinical management. 
Furthermore, it is possible to tackle unexplored areas of basic biomedical syphilis research 
concerning the natural history of the disease. This includes a thorough description of 
immune responses to T. pallidum. Such an investment will lay the foundation for potentially 
seminal discoveries that may lead to better and faster diagnostic tests, more efficacious 
antimicrobials, evidence-based disease management, and even a protective vaccine. These 
will ultimately be needed to substantially advance syphilis prevention and intervention.
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The 2016 Syphilis Summit proposed renewed and sustained support of biomedical 
syphilis research, and recommended that an influx of talent could accelerate the fight 
against this re-emerging ancient disease.
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